News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics reports positive safety and efficacy data from Phase 1 clinical trials of SON-1010, a novel immunotherapeutic drug for solid tumors, demonstrating extended half-life and clinical benefit in patients -
-
-
COMMUNIQUÉ DE PRESSE
VivaWell and Shen.AI Announce Strategic Partnership to Transform Health Monitoring in Mexico and Argentina
Shen.AI partners with VivaWell to revolutionize digital health in Mexico and Argentina, offering remote vital signs monitoring. This collaboration aims to redefine preventive healthcare and wellness